Open access
Open access
Powered by Google Translator Translator

Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.

31 Aug, 2022 | 11:45h | UTC

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Treatment De-Escalation With Locoregional Radiotherapy Appears Safe in cT1-2N1 Breast Cancer – Cancer Network

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.